Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Hearing abnormalities in patients treated with teprotumumab

Nature Reviews Endocrinology (2024)Cite this article

Subjects

The introduction of teprotumumab for the treatment of thyroid eye disease has dramatically improved management of this life-changing condition; however, clinical trials and experience in the clinic have revealed associated hearing abnormalities.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Localization of IGF-1R-mediated otologic actions.

References

  1. Smith, T. J. & Hegedüs, L. Graves’ disease. N. Engl. J. Med. 375, 1552–1565 (2016).

    Article  PubMed  Google Scholar 

  2. Smith, T. J. et al. Teprotumumab for thyroid-associated ophthalmopathy. N. Engl. J. Med. 376, 1748–1761 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Douglas, R. S. et al. Teprotumumab for the treatment of active thyroid eye disease. N. Engl. J. Med. 382, 341–352 (2020).

    Article  CAS  PubMed  Google Scholar 

  4. Fernando, R., Caldera, O. & Smith, T. J. Therapeutic IGF-I receptor inhibition alters fibrocyte immune phenotype in thyroid-associated ophthalmopathy. Proc. Natl Acad. Sci. USA 118, e2114244118 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Douglas, R. S. et al. Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity. J. Clin. Endocrinol. Metab. 109, 25–35 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  6. Gao, L. & Nakagawa, T. Insulin-like growth factor 1: role in the auditory system and therapeutic potential in otology. Curr. Opin. Otolaryngol. Head Neck Surg. 28, 286–290 (2020).

    Article  PubMed  Google Scholar 

  7. Kiely, K. M., Gopinath, B., Mitchell, P., Browning, C. J. & Anstey, K. J. Evaluating a dichotomized measure of self-reported hearing loss against gold standard audiometry: prevalence estimates and age bias in a pooled national data set. J. Aging Health 24, 439–458 (2012).

    Article  PubMed  Google Scholar 

  8. Bance, M., Tysome, J. R. & Smith, M. E. Patulous Eustachian tube (PET), a practical overview. World J. Otorhinolaryngol. Head Neck Surg. 5, 137–142 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  9. Tran, Y. et al. Establishing multifactorial risk factors for adult-onset hearing loss: A systematic review with topic modelling and synthesis of epidemiological evidence. Prev. Med. 180, 107882 (2024).

    Article  PubMed  Google Scholar 

  10. Douglas, R. S. et al. A prospective study examining audiometry outcomes following teprotumumab treatment for thyroid eye disease. Thyroid 34, 134–137 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Pennsylvania School of Medicine, Philadelphia, PA, USA

    Jason A. Brant

  2. University of California San Diego School of Medicine, San Diego, CA, USA

    Don O. Kikkawa

  3. University of Michigan Medical School, Ann Arbor, MI, USA

    Terry J. Smith

Authors
  1. Jason A. Brant
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Don O. Kikkawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Terry J. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Terry J. Smith.

Ethics declarations

Competing interests

J.A.B. is a consultant for Amgen. D.O.K. is a consultant for Amgen, Immunovant and Lassen Therapeutics. T.J.S. has issued patents for targeting IGF-IR as a therapy for autoimmune diseases, including TED, which are held by Lundquist Institute/UCLA and University of Michigan. T.J.S. is a consultant for Amgen, Viridian Therapeutics, Lundbeck, Argenx, Lassen Therapeutics and Minghui Pharmaceuticals.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Brant, J.A., Kikkawa, D.O. & Smith, T.J. Hearing abnormalities in patients treated with teprotumumab. Nat Rev Endocrinol (2024). https://doi.org/10.1038/s41574-024-00995-9

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/s41574-024-00995-9

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing